medroxyprogesterone acetate
Other / unclassified targets PGR via activation
Regulatory milestones approvals, filings & regulatory actions · 7 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DEPO-SUBQ PROVERA 104 | — | 2020-12-04 | fda.gov ↗ |
| Label expansions (2) | US (FDA) | DEPO-PROVERA | — | 2010-10-15 – 2011-07-28 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | PROVERA | — | 1979-06-06 – 1998-08-04 | fda.gov ↗ |
| Approved | US (FDA) | PROVERA | — | 1959-06-18 | fda.gov ↗ |
Trials 105 · started per year
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04423068 | Dec 2020 → Apr 2022 | pregnancy disorder | Children's Mercy Hospital Kansas City | Completed | No outcome recorded |
| Phase 0 | NCT03197961 | Nov 2017 → Apr 2018 | HIV infectious disease | Sharon Achilles | Completed | No outcome recorded |
| Phase 114 trials | ||||||
| Phase 1 | NCT04893798 | Sep 2021 → Jul 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04682353 | Dec 2020 → Jul 2022 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03700658 | Jan 2019 → Oct 2020 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03443089 | Mar → Apr 2017 | — | Galeno Desenvolvimento de Pesquisas Clínicas | Completed | No outcome recorded |
| Phase 1 | NCT02732418 | Dec 2016 → May 2018 | — | FHI 360 | Completed | No outcome recorded |
| Phase 1 | NCT02817464 | Oct 2016 → Dec 2018 | pregnancy disorder | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02456584 | Sep 2015 → Aug 2018 | — | FHI 360 | Completed | No outcome recorded |
| Phase 1 | NCT02272647 | Dec 2014 → Dec 2016 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT01265017 | Jul 2012 → Jun 2020 | type 1 diabetes mellitus | Sansum Diabetes Research Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT01421368 | Mar 2012 → Mar 2014 | — | CONRAD | Completed | No outcome recorded |
| Phase 1 | NCT01231451 | Dec 2010 → Jun 2011 | HIV infectious disease | St Stephens Aids Trust | Withdrawn | No outcome recorded |
| Phase 1 | NCT00630435 | Feb → Jun 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00401219 | Nov 2006 → Feb 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00044837 | — | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03264781 | Aug 2016 → Dec 2017 | uterine disorder | Chulalongkorn University | Unknown | No outcome recorded |
| Phase 1/2 | NCT01699022 | Jun 2010 → Jul 2011 | — | Sun Pharmaceutical Industries, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT00161447 | May 2004 → Apr 2006 | — | University of Washington | Completed | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT07377734 | Jan 2026 → Dec 2027 expected | atypical endometrial hyperplasia, endometrial cancer | Wang Jianliu | Recruiting | No outcome recorded |
| Phase 2 | NCT06979596 | Aug 2025 → Nov 2027 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06914297 | Apr 2025 → Oct 2027 expected | endometrial cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT05675787 | Jan 2023 → Aug 2025 overdue | atypical endometrial hyperplasia, endometrial carcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04997811 | Dec 2021 → Jan 2025 | myelodysplastic syndrome | Prof. Janet Dunn | Unknown | No outcome recorded |
| Phase 2 | NCT03567655 | Jul 2018 → Oct 2022 | endometrial cancer | Asan Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02412436 | Nov 2015 → Jun 2017 | HIV infectious disease, tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT02335203 | Feb 2015 → Mar 2016 | complex endometrial hyperplasia, endometrial endometrioid adenocarcinoma | Women and Infants Hospital of Rhode Island | Unknown | No outcome recorded |
| Phase 2 | NCT01296152 | May 2011 → Oct 2012 | HIV infectious disease | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Completed | No outcome recorded |
| Phase 2 | NCT00577122 | Jul 2007 → Dec 2011 | estrogen-receptor negative breast cancer, female breast carcinoma, progesterone-receptor negative breast cancer | Indiana University | Completed | No outcome recorded |
| Phase 2 | NCT00370019 | Aug 2006 → Dec 2011 | primary ovarian failure | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Withdrawn | No outcome recorded |
| Phase 2 | NCT00064025 | Apr 2004 → Sep 2010 | endometrial adenosquamous carcinoma, endometrioid adenocarcinoma, endometrium adenocarcinoma, uterine corpus cancer | Gynecologic Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00033358 | Feb 2002 → Oct 2007 | endometrial cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00003179 | Nov 1998 → Feb 2006 | endometrial cancer | Gynecologic Oncology Group | Terminated | No outcome recorded |
| Phase 2/38 trials | ||||||
| Phase 2/3 | NCT07319429 | Jan 2026 → Dec 2027 expected | endometrial cancer, infertility disorder | Fudan University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05973253 | Apr → Jun 2023 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
| Phase 2/3 | NCT05565573 | Nov 2022 → Jul 2024 | — | Hua Li | Unknown | No outcome recorded |
| Phase 2/3 | NCT05255653 | Nov 2021 → Jan 2030 expected | endometrial cancer | Leiden University Medical Center | Recruiting | No outcome recorded |
| Phase 2/3 | NCT03463252 | Apr 2018 → Dec 2025 overdue | atypical endometrial hyperplasia, endometrial cancer | West China Second University Hospital | Recruiting | No outcome recorded |
| Phase 2/3 | NCT00083824 | Mar 2004 → Feb 2007 | coronary atherosclerosis | Tufts University | Completed | No outcome recorded |
| Phase 2/3 | NCT00088153 | Jul 2003 → Feb 2011 | anorexia nervosa | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT00066157 | Sep 2001 → Dec 2007 | Alzheimer disease | University of Wisconsin, Madison | Completed | No outcome recorded |
| Phase 324 trials | ||||||
| Phase 3 | NCT05326087 | Jun 2026 → Dec 2027 expected | polycystic ovary syndrome | ShangHai Ji Ai Genetics & IVF Institute | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07124195 | Aug 2025 → Oct 2026 expected | cancer, chemotherapy-induced toxicity | The First Affiliated Hospital of Xinxiang Medical College | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06145438 | Sep 2023 → Aug 2024 | ovarian endometriosis | Universitas Diponegoro | Completed | No outcome recorded |
| Phase 3 | NCT04414761 | Jun 2020 → Oct 2022 | — | ShangHai Ji Ai Genetics & IVF Institute | Completed | No outcome recorded |
| Phase 3 | NCT03675139 | Feb 2019 → May 2022 | endometrial hyperplasia without atypia | Xiaojun Chen | Completed | No outcome recorded |
| Phase 3 | NCT03300960 | Oct 2017 → Jun 2019 | infertility disorder | Instituto Valenciano de Infertilidad, IVI VALENCIA | Completed | No outcome recorded |
| Phase 3 | NCT03154125 | Sep 2017 → May 2020 | — | FHI 360 | Completed | No outcome recorded |
| Phase 3 | NCT02922348 | Mar 2016 → Dec 2018 | primary ovarian failure | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 3 | NCT02449161 | Aug 2015 → May 2021 | menstrual disorder | Guy Waddell | Terminated | No outcome recorded |
| Phase 3 | NCT01461824 | Sep 2011 → Apr 2015 | disease of bone structure, uterine disorder | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01011751 | Apr 2004 → Dec 2007 | prostate adenocarcinoma | Takeda | Completed | No outcome recorded |
| Phase 3 | NCT00564031 | Jan 2003 → Aug 2004 | — | Karolinska University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00030914 | Apr 2002 → Feb 2006 | — | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00026286 | Nov 2000 → Aug 2002 | breast cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00291369 | Dec 1999 → Feb 2005 | renal cell carcinoma | Centre Leon Berard | Completed | No outcome recorded |
| Phase 3 | NCT00000430 | Oct 1999 → Sep 2004 | osteoporosis | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Terminated | No outcome recorded |
| Phase 3 | NCT00002920 | Mar 1997 → Dec 2006 | breast cancer, endometrial cancer | SWOG Cancer Research Network | Completed | No outcome recorded |
| Phase 3 | NCT00000605 | Aug 1996 → Jul 2002 | coronary atherosclerosis, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000419 | Apr 1996 → Aug 2002 | systemic lupus erythematosus | NYU Langone Health | Terminated | No outcome recorded |
| Phase 3 | NCT00000601 | Jul 1995 → Jun 2000 | intermediate coronary syndrome | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00000559 | Mar 1995 → Aug 2001 | coronary artery disorder, myocardial ischemia | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00319566 | Jul 1992 → Jul 2001 | coronary artery disorder | University of California, San Francisco | Completed | No outcome recorded |
| Phase 3 | NCT00000466 | Sep 1987 → Oct 2000 | coronary artery disorder, diabetes mellitus, hyperlipoproteinemia, hypertensive disorder +3 | National Heart, Lung, and Blood Institute (NHLBI) | Completed | No outcome recorded |
| Phase 3 | NCT00416429 | ? → Feb 2005 | kidney cancer | Centre Leon Berard | Completed | No outcome recorded |
| Phase 423 trials | ||||||
| Phase 4 | NCT07462663 | Jan 2027 → Apr 2031 expected | atypical endometrial hyperplasia, endometrial cancer, intraepithelial neoplasia, morbid obesity | Hospital Universitari de Bellvitge | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06665997 | Jun 2025 → Jul 2028 expected | sickle cell disease | University of Pennsylvania | Recruiting | No outcome recorded |
| Phase 4 | NCT06816901 | Mar → Jul 2025 | lactation disease | University of California, San Diego | Completed | No outcome recorded |
| Phase 4 | NCT06637189 | Oct 2024 → Jun 2025 overdue | — | Ginefiv | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05651282 | Mar 2023 → Nov 2025 | endometrial cancer | University of British Columbia | Completed | No outcome recorded |
| Phase 4 | NCT05726903 | Dec 2022 → Nov 2023 | — | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 4 | NCT05491343 | Aug → Dec 2022 | arteriovenous hemangioma/malformation | HaEmek Medical Center, Israel | Unknown | No outcome recorded |
| Phase 4 | NCT04669678 | Nov 2021 → Feb 2024 | HIV infectious disease | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 4 | NCT04910711 | Oct 2021 → Aug 2023 | HIV infectious disease | Botswana Harvard AIDS Institute Partnership | Unknown | No outcome recorded |
| Phase 4 | NCT04654741 | Sep 2020 → Feb 2022 | infertility disorder | Casa di Cura Privata Villa Mafalda | Unknown | No outcome recorded |
| Phase 4 | NCT03844633 | Mar 2019 → May 2021 | — | Ohio State University | Terminated | No outcome recorded |
| Phase 4 | NCT03034057 | Aug 2017 → Dec 2018 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02534688 | Jun 2015 → May 2016 | endometriosis | King Chulalongkorn Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02357368 | Feb 2015 → Oct 2019 | HIV infectious disease | Lisa Haddad | Completed | No outcome recorded |
| Phase 4 | NCT01966575 | Oct 2013 → Sep 2015 | infertility disorder, polycystic ovary syndrome | University of British Columbia | Withdrawn | No outcome recorded |
| Phase 4 | NCT01299116 | Dec 2011 → Jun 2016 | — | FHI 360 | Completed | No outcome recorded |
| Phase 4 | NCT01109979 | Dec 2009 → Jan 2012 | cardiovascular disorder | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01148420 | Jan 2009 → Oct 2010 | uterine disorder | Women's Health Care Clinic, Torrance, California | Completed | No outcome recorded |
| Phase 4 | NCT01056042 | Jun 2007 → Apr 2011 | endometriosis | Prince of Songkla University | Completed | No outcome recorded |
| Phase 4 | NCT00294463 | Feb 2003 → Mar 2005 | osteoporosis | Erasmus Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00169299 | Jun 2001 → Sep 2004 | — | Kaiser Permanente | Unknown | No outcome recorded |
| Phase 4 | NCT00139685 | Apr 1998 → Aug 2006 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT00392093 | Nov 1997 → Dec 2001 | systemic lupus erythematosus | National Institute of Medical Sciences and Nutrition Salvador Zubiran | Completed | No outcome recorded |
| Phase not applicable17 trials | ||||||
| — | NCT06549855 | Oct 2024 → Jul 2029 expected | endometrial cancer, endometrioid adenocarcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06468215 | Jul 2024 → Jul 2028 expected | endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07488949 | Apr 2024 → Dec 2030 expected | chronic endometritis | Fang Wang | Recruiting | No outcome recorded |
| — | NCT05767086 | Mar 2023 → Sep 2024 | infertility disorder | Bezmialem Vakif University | Completed | No outcome recorded |
| — | NCT05044962 | Nov 2021 → Mar 2027 expected | HIV infectious disease | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| — | NCT04710017 | Feb 2021 → Feb 2022 | uterine disorder | Assiut University | Completed | No outcome recorded |
| — | NCT05945407 | Aug 2016 → Dec 2023 overdue | endometrial cancer, endometrial endometrioid adenocarcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| — | NCT02984696 | Mar 2015 → Oct 2016 | functional hypothalamic amenorrhea | Catholic University of the Sacred Heart | Unknown | No outcome recorded |
| — | NCT02146248 | May 2014 → Jan 2015 | fallopian tube disorder | Jeffrey Jensen | Completed | No outcome recorded |
| — | NCT01578447 | Apr 2012 → Mar 2013 | — | Johns Hopkins Bloomberg School of Public Health | Completed | No outcome recorded |
| — | NCT01143207 | May 2010 → Oct 2011 | — | FHI 360 | Completed | No outcome recorded |
| — | NCT00668603 | Aug 2005 → Mar 2008 | cardiovascular disorder | University of Helsinki | Completed | No outcome recorded |
| — | NCT00350480 | Apr 2003 → Jun 2005 | menstrual disorder, uterine disorder | Kaiser Permanente | Completed | No outcome recorded |
| — | NCT00016601 | Jun 2001 → May 2004 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| — | NCT00061711 | Jul 2000 → Dec 2005 | — | National Institute on Aging (NIA) | Completed | No outcome recorded |
| — | NCT00006133 | Jun 2000 → ? | systemic lupus erythematosus | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| — | NCT00006324 | Dec 1999 → Dec 2002 | HIV infectious disease | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
Also used as a comparator or background therapy in 60 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT05760144 Comparator | Jul 2023 → Nov 2026 expected | — | Oregon Health and Science University | Recruiting | No outcome recorded |
| Phase 0 | NCT03395756 Comparator | Aug 2018 → Oct 2020 | — | University of Southern California | Completed | No outcome recorded |
| Phase 0 | NCT03018249 Background | Oct 2017 → Apr 2018 | endometrial endometrioid adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT02792153 Background | Dec 2016 → Aug 2018 | anorexia nervosa | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 1 | NCT00543634 Comparator | Oct → Dec 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00830414 Comparator | Apr → Sep 2002 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01791413 Comparator | Mar 2012 → Mar 2013 | endometriosis | Mahidol University | Completed | No outcome recorded |
| Phase 213 trials | ||||||
| Phase 2 | NCT07714070 Background | Jul 2026 → Sep 2027 expected | atypical endometrial hyperplasia, endometrial cancer, progesterone resistance | Peking University People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05247268 Comparator | Mar 2022 → Mar 2027 expected | endometrial carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT03689543 Background | May 2019 → Sep 2024 | — | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Phase 2 | NCT03018366 Comparator | Jan 2017 → Feb 2023 | cardiovascular disorder, functional hypothalamic amenorrhea | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT02228681 Comparator | May 2015 → Jan 2018 | endometrial cancer | GOG Foundation | Completed | No outcome recorded |
| Phase 2 | NCT02894151 Comparator | Apr 2015 → May 2016 | endometriosis | Chulalongkorn University | Completed | No outcome recorded |
| Phase 2 | NCT02064725 Background | Sep 2014 → Jan 2018 | endometrial carcinoma | Kevelt AS | Unknown | No outcome recorded |
| Phase 2 | NCT00807625 Comparator | Nov 2008 → Jul 2010 | HIV infectious disease | University of Alabama at Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT00739830 Comparator | Aug 2008 → Feb 2011 | endometrial cancer | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 2 | NCT00420342 Comparator | Jan 2007 → Sep 2008 | hypertensive disorder | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00437658 Comparator | Dec 2006 → Nov 2008 | endometriosis | AbbVie | Completed | No outcome recorded |
| Phase 2 | NCT00302731 Comparator | Feb 2006 → Jan 2014 | premature menopause | Jeanne Drisko, MD, CNS, FACN | Terminated | No outcome recorded |
| Phase 2 | NCT00332553 Background | Feb 2002 → May 2004 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01472315 Comparator | Jan → Nov 2000 | sleep apnea syndrome | Turku University Hospital | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT06904274 Comparator | Nov 2025 → Jun 2026 | endometrial hyperplasia without atypia | Bayer | Terminated | No outcome recorded |
| Phase 3 | NCT06671548 Background | Jan 2024 → Nov 2026 expected | leiomyoma | Qilu Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT02943655 Comparator | Nov 2017 → Oct 2020 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02732808 Background | Sep 2014 → Apr 2016 | female infertility | Royan Institute | Completed | No outcome recorded |
| Phase 3 | NCT02103764 Comparator | Aug 2013 → Jul 2018 | uterine disorder | Mahidol University | Unknown | No outcome recorded |
| Phase 3 | NCT00808132 Comparator | Jan 2009 → Feb 2011 | osteoporosis | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00360490 Comparator | Jul 2006 → Jun 2008 | menstrual disorder | Bayer | Completed | No outcome recorded |
| Phase 3 | NCT00745108 Comparator | Oct 2001 → Jul 2005 | — | Organon and Co | Completed | No outcome recorded |
| Phase 3 | NCT03097120 Comparator | Jan 1995 → Jan 2001 | heart disorder | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 3 | NCT00004650 Background | Aug 1993 → ? | osteoporosis | National Institute of Dental and Craniofacial Research (NIDCR) | Completed | No outcome recorded |
| Phase 3 | NCT00191113 Background | Feb 1989 → Dec 2007 | Turner syndrome | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 412 trials | ||||||
| Phase 4 | NCT05505435 Comparator | Aug 2022 → Sep 2023 | — | Northwestern University | Completed | No outcome recorded |
| Phase 4 | NCT04814927 Comparator | Mar 2021 → Dec 2022 | mucositis | Eastern Virginia Medical School | Completed | No outcome recorded |
| Phase 4 | NCT03309176 Comparator | Jun 2016 → Nov 2017 | anovulation | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02872818 Comparator | Oct 2014 → Mar 2015 | hyperplasia | Kayseri Education and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02103660 Comparator | Apr 2014 → Mar 2017 | HIV infectious disease | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT02340013 Comparator | Jul 2013 → Apr 2015 | female infertility | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01822288 Comparator | Nov 2012 → Jul 2021 | — | Far Eastern Memorial Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01776203 Comparator | Jan 2012 → Apr 2014 | uterine disorder | Kaiser Permanente | Terminated | No outcome recorded |
| Phase 4 | NCT01463202 Comparator | Nov 2011 → Feb 2017 | lactation disease, postpartum depression | Beatrice Chen | Completed | No outcome recorded |
| Phase 4 | NCT01698164 Comparator | Dec 2008 → Oct 2012 | breast cancer, cardiovascular disorder, osteoporosis, premature menopause | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01074892 Comparator | May 2005 → Dec 2013 | endometrial disorder | University Hospital of North Norway | Completed | No outcome recorded |
| Phase 4 | NCT00860964 Background | Feb 1998 → Feb 2003 | osteoporosis | Peking Union Medical College | Completed | No outcome recorded |
| Phase not applicable16 trials | ||||||
| — | NCT07032506 Background | May 2026 → Sep 2029 expected | adhesions of uterus | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| — | NCT07020429 Background | Sep 2025 → Jul 2030 expected | primary ovarian failure | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| — | NCT06304220 Comparator | Jul → Sep 2024 | female infertility | NextFertility | Unknown | No outcome recorded |
| — | NCT02855632 Background | Aug 2016 → Dec 2018 | adhesions of uterus | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| — | NCT02550067 Comparator | Dec 2015 → Oct 2018 | HIV infectious disease | FHI 360 | Completed | No outcome recorded |
| — | NCT02293694 Comparator | Sep 2015 → Jan 2017 | — | FHI 360 | Completed | No outcome recorded |
| — | NCT01718444 Comparator | Mar 2015 → Jun 2016 | infertility disorder, polycystic ovary syndrome | University of Illinois at Chicago | Terminated | No outcome recorded |
| — | NCT02122198 Comparator | Sep 2014 → May 2017 | cardiovascular disorder, cognitive disorder | University of Colorado, Denver | Completed | No outcome recorded |
| — | NCT01418209 Comparator | Nov 2011 → Jan 2013 | — | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| — | NCT02144259 Comparator | Apr 2011 → Oct 2012 | — | University of Pennsylvania | Completed | No outcome recorded |
| — | NCT01191203 Comparator | Jul 2010 → Dec 2011 | HIV infectious disease | Emory University | Completed | No outcome recorded |
| — | NCT01019369 Comparator | Mar 2010 → Jan 2011 | — | Carolyn L. Westhoff | Completed | No outcome recorded |
| — | NCT00743574 Background | Aug 2008 → Feb 2013 | polycystic ovary syndrome, vitamin D deficiency | Yale University | Completed | No outcome recorded |
| — | NCT00563576 Background | Sep 2007 → Feb 2009 | hemometra | Columbia University | Completed | No outcome recorded |
| — | NCT00828542 Comparator | Jul 2007 → Feb 2008 | — | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT01087593 Background | Aug 2001 → Oct 2007 | fibromyalgia | Ostergotland County Council, Sweden | Terminated | No outcome recorded |
Press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-09-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Reintroduction of Generic Depo-Provera® in the United States tevapharm.com ↗ |
| 2017-05-08 | Pfizer | Collaboration Helps Broaden Access to Pfizer’s Contraceptive, Sayana® Press (medroxyprogesterone acetate), for Women in Some of the World’s Poorest Countries pfizer.com ↗ |
| 2004-10-27 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Medroxyprogesterone Acetate Pre-Filled Syringe tevapharm.com ↗ |
| 2004-07-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval Of Medroxyprogesterone Acetate Injectable Suspension tevapharm.com ↗ |
Evidence & citations 54 cited values
Every value below carries the sentence it was read from. 177 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | medroxyprogesterone acetate | “Study participants were 256 women who completed the Estrogen Replacement and Atherosclerosis (ERA) trial, a placebo-controlled, randomized trial that examined the effects of...” PMID 19155011 ↗ Dec 2008102“Daily administration of medroxyprogesterone acetate 10 mg (Progestrone®, 5mg bid; Aboureihan, Iran) is added beginning on stimulation day 12 for cases in which post-ovulation...” NCT02732808 ↗ “High-potency progestin given orally as background therapy in both groups: medroxyprogesterone acetate 250-500 mg/day or megestrol acetate 160-320 mg/day, with the specific...” NCT07714070 ↗ “2 weeks of oral estradiol (2 mg daily) or transdermal (two 0.1 mg patches changed twice weekly) estradiol supplementation followed by 1 week of oral or transdermal estradiol...” NCT07032506 ↗ “Clinical Efficacy and Pregnancy Outcomes of Doxycycline Combined With Medroxyprogesterone Acetate Therapy for Chronic Endometritis(CE) in Patients With Recurrent Reproductive...” NCT07488949 ↗ “OBJECTIVES: This study aimed to evaluate and compare local tolerability of investigational drug TV-46046 and reference drug Depo-subQ Provera 104, both containing...” PMID 37823034 ↗ Sep 2023 “Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or...” NCT02064725 ↗ “This study will compare the bioavailabity of three new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed...” NCT00401219 ↗ “To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and...” NCT00139685 ↗ “The participants were treated in randomized order with either transdermal estradiol gel (1 mg), oral estradiol valerate (2 mg) with or without medroxyprogesterone acetate (5...” PMID 20443719 ↗ Oct 2010 “consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of...” NCT02855632 ↗ “A Randomized Comparison Of Medroxyprogesterone Acetate (MA) And Observation For Prevention Of Endometrial Pathology In Postmenopausal Breast Cancer Patients Treated With...” NCT00002920 ↗ “Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients” NCT02534688 ↗ “1. Conjugated equine estrogens 0.625 mg/day plus 5 mg/day of medroxyprogesterone acetate p.o. for the first 10 days per-month (Premarin and Cycrin, respectively, Laboratorios Wyeth).” NCT00392093 ↗ “comparing oral medroxyprogesterone acetate 20 mg and a monophasic combination OC containing 1 mg norethindrone and 35 mug of ethinyl estradiol, each administered three times per day” PMID 17012455 ↗ Oct 2006 “The study group included 20 patients treated with 1 mg of transdermal estradiol daily and 10mg of oral Medroxyprogesterone acetate from 16th to 24th day of therapy for six months.” NCT02984696 ↗ “This current trial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes.” PMID 16505409 ↗ Feb 2006 “receive conjugated equine estrogens 0.45 mg combined with medroxyprogesteroneacetate 1.5 mg placed in a placebo capsule to disguise contents from participant and study team” NCT00302731 ↗ “Intramuscular injectable depot medroxyprogesterone acetate (1 mL of medroxyprogesterone acetate sterile aqueous suspension 150 mg/mL) provided within 48 hours of childbirth” NCT03844633 ↗ “Medroxyprogesterone acetate Progevera® 10 mg/day orally from the first day of controlled ovarian hyperstimulation (COH) until the day of trigger with agonist (GnRH-a).” NCT06304220 ↗ “Administration of a single intramuscular dose of an injectable formulation containing medroxyprogesterone acetate 25 mg/mL + estradiol cypionate 5 mg/mL after a” NCT03443089 ↗ “Clinical trial to evaluate pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate after subcutaneous administration of Depo-Provera.” PMID 33485608 ↗ Jan 2021 “One of the agents studied to prepare the endometrium before ablation is medroxyprogesterone acetate (MPA) as injectables (DMPA) and oral.” NCT02449161 ↗ “Sayana Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) prefilled in a Uniject injection system” PMID 24332432 ↗ Nov 2013 “They will take oral high-dose progestin (Medroxyprogesterone Acetate 250mg-500mg/d or Megestrol Acetate 160mg-320mg/d) daily.” NCT07377734 ↗ “PPOS group: Women will receive oral MPA (medroxyprogesterone acetate)10mg qd from Day 3 till the day of ovulation trigger.” NCT05326087 ↗ “Cyclofem is a combined injectable contraceptive, containing medroxyprogesterone acetate (MPA) and estradiol cypionate.” PMID 23265980 ↗ Dec 2012 “DMPA contains 104 mg of medroxyprogesterone acetate in 0.65 mL of fluid, administered by subcutaneous injection” NCT04814927 ↗ “Typical regimens include medroxyprogesterone acetate (400-600 mg/day) or megestrol acetate (160-320 mg/day).” NCT07462663 ↗ “Medroxyprogesterone Acetate 25 mg plus Estradiol Cypionate 5 mg (Cyclofem®) 0.5 ml IM injection single dose” NCT03264781 ↗ “The PCT consists of taking a ten-day course of medroxyprogesterone acetate (Provera) 10 mg per os daily.” NCT05651282 ↗ “Starting from day 17 of treatment, medroxyprogesterone acetate will be added at a dose of 10 mg per day.” NCT07020429 ↗ “Patients will receive medroxyprogesterone acetate ("FARLUTAL") 250-500mg/d or megestrol acetate” NCT05945407 ↗ “1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg” NCT01109979 ↗ “cyclic medroxyprogesterone acetate (MPA), 10 milligrams per day for 12 days per month” NCT00000466 ↗ “Patients receive oral medroxyprogesterone acetate (Provera) once daily for 3 months.” NCT00003179 ↗ “One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours” NCT03300960 ↗ “Premarin®/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations” NCT00543634 ↗ “DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL)” NCT02550067 ↗ “The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA).” NCT03154125 ↗ “The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)” NCT02732418 ↗ “conjugated equine estrogen 0.625 mg +/- 2.5 mg medroxyprogesterone acetate” PMID 16186076 ↗ Oct 2005 “Administration of 150 mg intramuscular depot medroxyprogesterone acetate” NCT03395756 ↗ “medroxyprogesterone acetate (2 mg) administered orally once daily” NCT06671548 ↗ “adding 4mg medroxyprogesterone acetate, once a day, for 12 days” NCT01698164 ↗ “Conjugated Estrogen (CE) Plus Medroxyprogesterone Acetate (MPA)” NCT00745108 ↗ “Premarin®/medroxyprogesterone acetate (MPA) combination tablet” NCT00630435 ↗ “medroxyprogesterone acetate (MPA), i.e. Provera” NCT01966575 ↗ “medroxyprogesterone acetate (MPA, 500 mg qdpo)” NCT06914297 ↗ “medroxyprogesterone acetate (MPA) monotherapy” NCT00577122 ↗ “Drug: medroxyprogesterone acetate” NCT01148420 ↗ “medroxyprogesterone acetate (MPA)” NCT03463252 ↗ “Medroxyprogesterone Acetate” NCT03567655 ↗ “Medroxyprogesterone acetate” NCT01718444 ↗ |
| Known as | Adgyn medro | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Amen | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | angonghuangtitong | “Patients in group A will orally take MPA (Medroxyprogesterone Acetate) (angonghuangtitong, Xianju pharmaceuticals, China)10mg daily from tenth day of menstruation for 15 days...” NCT03675139 ↗ |
| Known as | Climanor | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Curretab | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Cycrin | “1. Conjugated equine estrogens 0.625 mg/day plus 5 mg/day of medroxyprogesterone acetate p.o. for the first 10 days per-month (Premarin and Cycrin, respectively, Laboratorios Wyeth).” NCT00392093 ↗ |
| Known as | Depo-Medroxyprogesterone Acetate | “DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide” NCT04669678 ↗6“150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks” NCT02103660 ↗ “Depo-medroxyprogesterone acetate (DepoProvera®)” NCT02146248 ↗ “depomedroxyprogesterone acetate (DMPA)” PMID 16940442 ↗ Aug 2006 |
| Known as | Depo-progevera | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Depo-Provera | “To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and...” NCT00139685 ↗13“Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ...” NCT01299116 ↗ “Patients receive medroxyprogesterone acetate suspension (Depo- Provera) intramuscularly once monthly for 3 months (days 1, 31, and 62).” NCT00003179 ↗ “Millions of women around the world use depot medroxyprogesterone acetate (DMPA, trade name Depo-Provera) for prevention of pregnancy.” NCT02412436 ↗ “Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women” NCT00016601 ↗ “using an injectable contraception, Depot Medroxyprogesterone Acetate (Depo-Provera), can reduce the pain” NCT06665997 ↗ “Depot medroxyprogesterone acetate (DMPA) is a generic form of the DepoProvera® shot.” NCT01461824 ↗ “subcutaneous depot medroxyprogesterone acetate (DMPA-SC; also known as depo-provera)” NCT00437658 ↗ “Depo-medroxyprogesterone acetate (DMPA) also called Depo-Provera” NCT05760144 ↗ “who want to use DMPA (Depo-Provera; Pfizer Corp.)” NCT03844633 ↗ “Depo-medroxyprogesterone acetate (DepoProvera®)” NCT02146248 ↗ “MedroxyPROGESTERone Injection [Depo-Provera]” NCT05491343 ↗ |
| Known as | Depo-provera oncology | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Depo-SubQ Provera 104 | “Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ...” NCT01299116 ↗ |
| Known as | DepoProvera, depot medroxyprogesterone acetate (DMPA) | “DepoProvera, depot medroxyprogesterone acetate (DMPA)” NCT02144259 ↗ |
| Known as | Depot medroxyprogesterone acetate | “Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ...” NCT01299116 ↗14“The objective of this study is to explore the potential of depot medroxyprogesterone acetate (DMPA) given as a 150-mg intramuscular injection for use as an emergency contraceptive.” NCT03395756 ↗ “Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject (Pfizer, Inc., USA).” NCT02293694 ↗ “one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection” NCT03197961 ↗ “Depot medroxyprogesterone acetate, brand name Depo Provera 150mg/ml, injected intramuscularly, every month for 3 months” NCT06145438 ↗ “DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.” NCT02144259 ↗ “DMPA (depot medroxyprogesterone acetate or the 'depot' injection)” NCT01231451 ↗ |
| Known as | depot medroxyprogesterone acetate (DMPA) | “depot medroxyprogesterone acetate (DMPA)” NCT02293694 ↗ |
| Known as | Depot MPA | “For the patients in the Depot MPA Group, 150 mg depot MPA was given intramuscularly once every three months.” NCT02894151 ↗ |
| Known as | Depot-Medroxyprogestereone Acetate | “Drug: Depot-Medroxyprogestereone Acetate” NCT03395756 ↗ |
| Known as | DMPA | “Forty healthy women exclusively breastfeeding were randomized to receive either ETG-releasing implant 24-48 h after delivery (n=20) or depot medroxyprogesterone acetate (DMPA...” PMID 19913145 ↗ Jul 200919“To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and...” NCT00139685 ↗ “Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ...” NCT01299116 ↗ “Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients” NCT02534688 ↗ “Effectiveness of Levonorgestrel-intrauterine System (LNG-IUS) Versus Depot Medroxyprogesterone Acetate (DMPA) in Treatment of Pelvic Pain in Clinically Diagnosed Endometriotic Patients” NCT02894151 ↗ “The objective of this study is to explore the potential of depot medroxyprogesterone acetate (DMPA) given as a 150-mg intramuscular injection for use as an emergency contraceptive.” NCT03395756 ↗ “Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment.” NCT02550067 ↗ “OBJECTIVES: We evaluated the effect of immediate postpartum use of depot medroxyprogesterone acetate (DMPA) on the timing of lactogenesis stage II (LS-II).” PMID 39424123 ↗ Oct 2024 “Sayana Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) prefilled in a Uniject injection system” PMID 24332432 ↗ Nov 2013 “one dose of Depot medroxyprogesterone acetate (DMPA) 150mg will be administered to each participant as an intramuscular injection” NCT03197961 ↗ “DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide” NCT04669678 ↗ “DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide” NCT05044962 ↗ “Depot medroxyprogesterone acetate (DMPA) is a generic form of the DepoProvera® shot.” NCT01461824 ↗ “depot medroxyprogesterone acetate (DMPA) injectable contraceptive” NCT04910711 ↗ “Depot medroxyprogesterone acetate (DMPA)” NCT02357368 ↗ “Depot medroxyprogesterone acetate (DMPA)” NCT06665997 ↗ “Depo-medroxyprogesterone acetate (DMPA)” NCT01421368 ↗ “depomedroxyprogesterone acetate (DMPA)” PMID 16940442 ↗ Aug 2006 |
| Known as | DMPA-IM | “We assessed acceptability of SP versus intramuscular DMPA (DMPA-IM) among HIV-positive women and their care providers in Rakai, Uganda.” PMID 24332432 ↗ Nov 2013 |
| Known as | DMPA-SC | “subcutaneous depot medroxyprogesterone acetate (DMPA-SC; also known as depo-provera)” NCT00437658 ↗ |
| Known as | DP150CI | “To evaluate and compare Bone Mineral Density (BMD) in adolescent Depo-Provera Contraceptive Injection (DP150CI) users during depo medroxyprogesterone acetate (DMPA) therapy and...” NCT00139685 ↗ |
| Known as | FARLUTAL | “Patients will receive medroxyprogesterone acetate ("FARLUTAL") 250-500mg/d or megestrol acetate” NCT05945407 ↗1“General Name/Brand name:Farlutal tab. 500mg/ Pfizer” NCT03567655 ↗ |
| Known as | Farlutal 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Farlutal 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Farlutal 250 | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Farlutal 500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Farlutal inyectable | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | G03AC06 | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | gestapuran | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00564031 ↗ |
| Known as | Medroxiprogesterona | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | medroxy progesterone | “In this clinical trial, it is decided that 30 patients who are candidates for photorefractive keratectomy will receive a drop of prepared medroxyprogesterone randomly in one of...” NCT05973253 ↗35“Subjects with rest angina and no contraindications to hormone therapy were randomized to receive intravenous followed by oral conjugated estrogen for 21 days, intravenous...” NCT00000601 ↗ “The purpose of the study is to compare the pharmacokinetics and relative bioavailability of medroxyprogesterone in healthy female participants following subcutaneous injection...” NCT04893798 ↗ “Progesterone is a peanut based product and for patients with a peanut allergy we will replace this with a synthetic progestin at an equivalent dose, medroxyprogesterone 10mg.” NCT03018366 ↗ “Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks” NCT01087593 ↗ “22 AN girls were randomized to transdermal estradiol (plus cyclic medroxyprogesterone) or placebo in a double-blind study for 12 months.” PMID 22728230 ↗ Jun 2012 “The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).” NCT01418209 ↗ “oral medroxyprogesterone 10 mg daily or duphaston 10mg bd daily from Day 3 till the day of ovulation trigger” NCT04414761 ↗ “they will be prescribed medroxyprogesterone (Provera) 10 mg per day for first 12 calendar days of each month” NCT02922348 ↗ “estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise” NCT00860964 ↗ “eyes that received one drop of medroxy progesterone at the end of the photorefractive keratectomy(PRK)” NCT05973253 ↗ “currently or interested in using depo medroxyprogesterone (DMPA)” NCT05726903 ↗ “plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.” NCT02792153 ↗ “Medroxyprogesterone 150mg/ml 150 mg IM injection” NCT04423068 ↗ |
| Known as | medroxy progestrone acetat | “prepared drop of medroxy progestrone acetat 1%” NCT05973253 ↗ |
| Known as | Medroxyprogesterone 17-Acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00083824 ↗ |
| Known as | medroxyprogesterone acetate (MPA) | “medroxyprogesterone acetate (MPA)” NCT03463252 ↗ |
| Known as | medroxyprogesterone acetate (MPA), i.e. Provera | “medroxyprogesterone acetate (MPA), i.e. Provera” NCT01966575 ↗ |
| Known as | Medroxyprogesterone acetate component of lunelle | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Medroxyprogesterone acetate component of premphase | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Medroxyprogesterone acetate component of prempro | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Medroxyprogesteroni acetas | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | Meishiya | “Medroxyprogesterone acetate oral suspension (Meishiya®) (administered from Day 1 to 21, 5 ml, once daily)” NCT07124195 ↗ |
| Known as | MPA | “Patients with histologically confirmed grade 1 endometrioid adenocarcinoma with superficial myometrial invasion or patients with histologically confirmed grade 2 endometrioid...” NCT03567655 ↗33“Study participants were 256 women who completed the Estrogen Replacement and Atherosclerosis (ERA) trial, a placebo-controlled, randomized trial that examined the effects of...” PMID 19155011 ↗ Dec 2008 “OBJECTIVES: This study aimed to evaluate and compare local tolerability of investigational drug TV-46046 and reference drug Depo-subQ Provera 104, both containing...” PMID 37823034 ↗ Sep 2023 “This study will compare the bioavailabity of three new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed...” NCT00401219 ↗ “OBJECTIVE: To compare medroxyprogesterone acetate (MPA) concentrations between HIV-positive women on antiretroviral therapy (ART) and HIV-negative women initiating depot...” PMID 31374188 ↗ Jul 2019 “Progestins (like medroxyprogesterone acetate, MPA) are female hormones and act through progesterone receptors, so it would be likely women to have less side effects from MPA...” NCT01472315 ↗ “Patients in group A will orally take MPA (Medroxyprogesterone Acetate) (angonghuangtitong, Xianju pharmaceuticals, China)10mg daily from tenth day of menstruation for 15 days...” NCT03675139 ↗ “Common HT for menopausal syndrome with intact uterus includes tibolone, estradiol valerate (E2V) 1mg \& medroxyprogesterone acetate (MPA) 2.5 mg, and conjugated equine estrogens \& MPA.” NCT01822288 ↗ “Eligible patients will be randomly assigned in a two-by-two factorial design to either medroxyprogesterone (MPA), subcutaneous IFN, subcutaneous IL2, or a combination of IFN and IL2.” NCT00291369 ↗ “Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.” NCT01699022 ↗ “This current trial compared a single intramuscular dose of medroxyprogesterone acetate (MPA), depot preparation, versus daily oral venlafaxine as treatment for hot flashes.” PMID 16505409 ↗ Feb 2006 “The randomization will be done 2:1 ratio, meaning that for every two participants assigned to Mirena, one will be assigned to oral medroxyprogesterone acetate (MPA).” NCT06904274 ↗ “We hypothesized that clearance of medroxyprogesterone acetate (MPA) would increase when given with rifampicin and efavirenz, thus increasing risk of ovulation.” PMID 31504342 ↗ Jul 2020 “There were 104 premenopausal women with AUB-O randomized to desogestrel (DSG 150 µg/d, n = 50) or medroxyprogesterone acetate (MPA 10 mg/d, n = 54) group.” PMID 35102226 ↗ Jan 2022 “Patients will receive MPA (Medroxyprogesterone acetate) 250-500 mg by mouth daily plus atorvastatin 20mg by mouth daily for at least 3 months.” NCT05675787 ↗ “One of the agents studied to prepare the endometrium before ablation is medroxyprogesterone acetate (MPA) as injectables (DMPA) and oral.” NCT02449161 ↗ “Subjects received daily oral BZA 20 mg/CE 0.45 or 0.625 mg, BZA 20 mg, CE 0.45 mg/medroxyprogesterone acetate (MPA) 1.5 mg, or PBO.” PMID 24438370 ↗ Jan 2014 “DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide” NCT04669678 ↗ “DMPA (150 mg of depo-medroxyprogesterone acetate (MPA)/ml IMI) is the most commonly used injectable contraceptive worldwide” NCT05044962 ↗ “Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.” NCT00360490 ↗ “doxycycline alone versus doxycycline plus medroxyprogesterone acetate (MPA) in women with chronic endometritis (CE)” NCT07488949 ↗ “Provera (Medroxyprogesterone (MPA)/progestin) 10 mg per oral treatment for 6 months 10 day each cycle” NCT01074892 ↗ “Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA)” NCT06549855 ↗ “with oral medroxyprogesterone acetate (MPA) 500mg/d or megestrol acetate (MA) 320mg/d” NCT06468215 ↗ “cyclic medroxyprogesterone acetate (MPA), 10 milligrams per day for 12 days per month” NCT00000466 ↗ “One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours” NCT03300960 ↗ “Premarin®/Medroxyprogesterone Acetate (MPA) Compared With Reference Formulations” NCT00543634 ↗ “The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA).” NCT03154125 ↗ “The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)” NCT02732418 ↗ “Conjugated Estrogen (CE) Plus Medroxyprogesterone Acetate (MPA)” NCT00745108 ↗ “medroxyprogesterone acetate (MPA, 500 mg qdpo)” NCT06914297 ↗ “medroxyprogesterone acetate (MPA)” NCT00630435 ↗ “Medroxyprogesterone Acetate (MPA)” NCT02456584 ↗ |
| Known as | NSC-21171 | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | NSC-26386 | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | NSC-27408 | ChEMBL registry synonym — accepted as the source's own label CHEMBL717 ↗ |
| Known as | progest | “medroxyprogesterone acetate (progest)” NCT02943655 ↗ |
| Known as | Progestrone | “Daily administration of medroxyprogesterone acetate 10 mg (Progestrone®, 5mg bid; Aboureihan, Iran) is added beginning on stimulation day 12 for cases in which post-ovulation...” NCT02732808 ↗ |
| Known as | Provera | “Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.” NCT00360490 ↗6“Patients receive oral medroxyprogesterone acetate (Provera) once daily for 3 months.” NCT00003179 ↗ “medroxyprogesterone acetate (MPA, Provera)” NCT00350480 ↗ “Medroxyprogesterone (Provera)” NCT00743574 ↗ |
| Known as | Sayana Press | “SC MPA or Sayana® Press is a single-dose container with 104 mg medroxyprogesterone acetate (MPA) in 0.65 mL suspension for injection.” NCT04669678 ↗2“Sayana Press (SP), a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) prefilled in a Uniject injection system” PMID 24332432 ↗ Nov 2013 |
| Known as | TV-46046 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04682353 ↗ |
| Action | Activate | “Progesterone receptor agonist” CHEMBL717 ↗ |
| Action | Inhibit | “The putative role of the progestin is to reduce the responsiveness of the endometrium to estradiol by downregulating endometrial estrogen receptors.” NCT01776203 ↗ |
| Modality | Other / unclassified | “Medroxyprogesterone acetate is a synthetic progestin” NCT06637189 ↗ |
| Route | Oral | “Patients receive oral medroxyprogesterone acetate on days 1-14.” NCT00002920 ↗ |
| Target | PGR | “Progesterone receptor agonist” CHEMBL717 ↗ |